Brilacidin: Phase IIb start

Next month, Cellceutix will begin a double-blind, U.S. Phase IIb trial to compare brilacidin vs. Cubicin daptomycin in about 200-215 patients

Read the full 213 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE